Supplementary Appendix S1

Outcome
Patients were divided in 2 HP subgroups (nfHP and fHP), based on HRCT findings 9, 12, 13 : fibrosis was defined as the presence of reticulation, traction bronchiectasis and/or honeycombing on HRCT. HP patients without fibrosis on HRCT were included in the nfHP group, HP patients with fibrosis were included in the fHP group. Differences in baseline characteristics, survival and PFT evolution were assessed between the 2 groups.
Effect of corticosteroid therapy initiation on survival and FVC%/DLCO% decline was assessed. For survival analysis a binary parameter was used (ever-vs never-corticosteroid use). FVC% and DLCO% decline before corticosteroid initiation was compared to PFT decline after initiation. To minimize bias, PFT's after withdrawal of corticosteroid therapy were excluded. Survival analyses for corticosteroid dosage (maximal dosage of <40 mg vs >40 mg of prednisolone-equivalent) and duration of therapy (<6 months vs >6 months) was also performed.
Survival and PFT evolution regarding known/unknown exposure, exposure type (using binary parameter: birds vs mold) and exposure avoidance (using binary parameter: antigen avoided vs antigen not avoided) was assessed, comparable to corticosteroid treatment analysis. FVC% and DLCO% decline before antigen avoidance was compared to PFT decline afterwards.
PFTs 5 years before until 1 year after avoidance were used. Baseline characteristics, PFT evolution and survival of patients with known exposure were compared with patients without known exposure similarly to the analyses of the 2 HP subgroups. These analyses were also performed comparing different exposure types.
Statistical analysis
Baseline characteristics: continuous variables were analyzed using Student's t-tests and Mann-Whitney U-tests where appropriate. For discrete variables, chi-square tests and Fisher's exact tests were used, where appropriate. Patients who underwent lung transplantation were censored at the day of transplantation.
Survival analysis: outcome was based on 10-year survival. Data were displayed as Kaplan-Meier curves and analyzed using Cox proportional hazards models. In multivariate analyses, we corrected for age, gender and baseline FVC%. All multivariate analyses are shown in Supplementary Table 1.
PFT evolution: evolution of PFT was analyzed with linear mixed-effects models, using FVC% and DLCO% as outcome measurements (in separate analyses). Subject was corrected for as a random effect, both with random intercept and (independent) random slope. As PFT's were performed in both referring hospitals and the University Hospitals Leuven, the hospital where the PFT was performed was also corrected for as random intercept. In general, time, age, gender were accounted for as fixed effect.
For analysis of the PFT evolution of the different HP subgroups, PFT's from the first year of follow-up were used when untreated and actively exposed.
For the corticosteroid treatment analysis: PFT's from 5 year before until 1 year after the treatment initiation were used. PFTs after stopping corticosteroid treatment (and/or stopping immunosuppression treatment) were excluded. Corticosteroid use was accounted for as fixed effect, both with and without time-varying covariate. Exposure status was corrected for as fixed effect, immunosuppression use was correct for as a time-varying covariate.
For the antigen avoidance analysis: PFT's from 5 year before until 1 year after avoidance were used.
Exposure status as well as corticosteroid use was correct for with and without time-varying covariate, immunosuppression use was corrected for as time-varying covariate. Figure S1 : Inclusion of patients in the cohort.
Visualization of cohort formation and exclusion rates for the different analyses. *all patients missing in the specific survival analysis were also excluded in the respective PFT analysis (e.g. 25 patients with missing treatment data were excluded from the PFT analysis of corticosteroid treatment), apart from one patient which lacked survival data (excluded from the survival analysis but included in the PFT analysis). Other patients excluded from the PFT analysis were missing longitudinal PFT data. Definition of abbreviation: ILD = interstitial lung disease, HP diagnosis = Hypersensitivity pneumonitis diagnosis, MDD =
